Open Label, Single-cohort, and Single-center Phase II Study Evaluating Tumor-specific Immunity After Extracorporeal Photopheresis in Patients With Sézary Syndrome at Single-cell Resolution
Latest Information Update: 22 Feb 2024
At a glance
- Drugs Methoxsalen (Primary)
- Indications Sezary syndrome
- Focus Therapeutic Use
- 14 Mar 2023 Planned initiation date changed (estimated date of first participant enrollment) from 15 Nov 2022 to 31 Mar 2023.
- 02 Nov 2022 Planned initiation date changed from 15 Sep 2022 to 15 Nov 2022.
- 12 Aug 2022 Planned initiation date changed from 15 Jul 2022 to 15 Sep 2022.